Sean Maduck - 01 Sep 2022 Form 4 Insider Report for CORCEPT THERAPEUTICS INC (CORT)

Role
Officer
Signature
/s/ Joseph Douglas Lyon, as attorney-in-fact for Sean Maduck
Issuer symbol
CORT
Transactions as of
01 Sep 2022
Net transactions value
-$539,796
Form type
4
Filing time
06 Sep 2022, 20:50:20 UTC
Previous filing
22 Aug 2022
Next filing
04 Oct 2022
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction CORT Common Stock Options Exercise $82,250 +25,000 +46% $3.29* 79,618 01 Sep 2022 Direct
transaction CORT Common Stock Sale $646,000 -25,000 -31% $25.84 54,618 01 Sep 2022 Direct F1, F2
transaction CORT Common Stock Award $23,954 +922 +1.7% $25.98 55,540 01 Sep 2022 Direct F3, F4
transaction CORT Common Stock Award $0 +922 +1.7% $0.000000 56,462 01 Sep 2022 Direct F5
holding CORT Common Stock 10,000 01 Sep 2022 See Footnote F6
holding CORT Common Stock 10,000 01 Sep 2022 See Footnote F7

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction CORT Stock option (right to buy) Options Exercise $0 -25,000 -23% $0.000000 82,602 01 Sep 2022 Common Stock 15,000 $3.29 Direct F8
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The transaction was made pursuant to a 10b5-1 plan in effect at the time of the transaction.
F2 Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $25.82 to $25.94. Information on the exact number of shares sold at each sale price can be obtained from the issuer upon request.
F3 The Reporting Person purchased shares ("Purchase Plan Shares") of the Issuer's common stock pursuant to a purchase plan ("Purchase Plan") established under the Corcept Therapeutics Incorporated 2012 Incentive Award Plan on September 1, 2022.
F4 In accordance with the Purchase Plan, the price was established based on the closing price on the day of the purchase.
F5 Shares underlie unvested restricted stock awards granted to the Reporting Person by the Issuer under the Purchase Plan. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements under the Purchase Plan.
F6 Represents the shares held by Duckhill Capital, LLC of which the reporting person is President and disclaims beneficial ownership of the shares except to the extent of his pecuniary interest therein.
F7 Represents the shares held by Sean and Molly Maduck Living Trust of which the reporting person is a co-trustee.
F8 Fully exercisable.

Remarks:

President, Corcept Endocrinology The power of attorney under which this form was signed is on file with the Commission.